Phoenix Biotech Acquisition Corp. PBAXU
We take great care to ensure that the data presented and summarized in this overview for PHOENIX BIOTECH ACQUISITION CORP. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PBAXU
Top Purchases
Top Sells
About PBAXU
Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe. The company was incorporated in 2021 and is based in Oakland, California.
Insider Transactions at PBAXU
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 10
2024
|
Yk Bioventures Opportunities Gp I, LLC |
SELL
Open market or private sale
|
Indirect |
3,250,000
-12.56%
|
$0
$0.1 P/Share
|
|
Sep 25
2024
|
Stuart M Sloan > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
532,486
-2.47%
|
$0
$0.1 P/Share
|
|
Sep 25
2024
|
Brian G Atwood Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
19,358,578
+49.68%
|
-
|
|
Sep 25
2024
|
Christopher B Ehrlich Interim Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,312,983
+47.84%
|
-
|
|
Sep 25
2024
|
Kathleen Laporte Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
965,997
+50.0%
|
-
|
|
Feb 14
2024
|
Daniel E. Geffken Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
10,002
+50.0%
|
-
|
|
Feb 14
2024
|
Barbara Kosacz Director |
BUY
Other acquisition or disposition
|
Direct |
5,828
+50.0%
|
-
|
|
Feb 14
2024
|
Caroline M Loewy Director |
BUY
Other acquisition or disposition
|
Direct |
5,828
+50.0%
|
-
|
|
Feb 14
2024
|
Brian G Atwood Director |
BUY
Other acquisition or disposition
|
Indirect |
248,735
+43.67%
|
-
|
|
Feb 14
2024
|
Brian G Atwood Director |
BUY
Other acquisition or disposition
|
Direct |
125,000
+50.0%
|
-
|
|
Feb 14
2024
|
Christopher B Ehrlich Interim Chairman and CEO |
BUY
Other acquisition or disposition
|
Indirect |
3,600
+50.0%
|
-
|
|
Feb 14
2024
|
Christopher B Ehrlich Interim Chairman and CEO |
BUY
Other acquisition or disposition
|
Direct |
478,825
+50.0%
|
-
|
|
Feb 14
2024
|
Christopher B Ehrlich Interim Chairman and CEO |
SELL
Other acquisition or disposition
|
Indirect |
5,296,246
-50.95%
|
-
|
|
Feb 14
2024
|
Kathleen Laporte Director |
BUY
Other acquisition or disposition
|
Direct |
5,828
+50.0%
|
-
|
|
Feb 14
2024
|
Phoenix Biotech Sponsor, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
5,296,246
-50.95%
|
-
|
|
Feb 14
2024
|
Douglas Fisher President |
BUY
Other acquisition or disposition
|
Direct |
43,300
+50.0%
|
-
|
|
Oct 08
2021
|
Douglas Fisher President |
BUY
Other acquisition or disposition
|
Indirect |
10,000
+50.0%
|
-
|
|
Oct 08
2021
|
Christopher B Ehrlich Interim Chairman and CEO |
BUY
Other acquisition or disposition
|
Indirect |
36,733
+4.99%
|
$367,330
$10.0 P/Share
|
|
Oct 08
2021
|
Phoenix Biotech Sponsor, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
36,733
+4.99%
|
$367,330
$10.0 P/Share
|
Last 12 Months Summary
| Other acquisition or disposition | 927K shares |
|---|---|
| Exercise of conversion of derivative security | 25.6M shares |
| Other acquisition or disposition | 10.6M shares |
|---|---|
| Open market or private sale | 3.78M shares |